Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why TG Therapeutics Is Crashing Today

TheMotleyFool

0 0

Why TG Therapeutics Is Crashing TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Shares of biotechnology company TG Therapeutics (NASDAQ: TGTX) are down 15.3% in Monday's late trading following a downgrade from investment bank Goldman Sachs.

TG Therapeutics' drug pipeline may not be as marketable as many investors believe it will be, according to Goldman Sachs analyst Corinne Jenkins. She downgraded the stock to a sell on Monday, citing limited revenue potential of its planned portfolio that's mostly being built around a single drug called umbralisib.

Image source: Getty Images.

Source Fool.com

Like: 0

TGTX

Teilen